Form D · Biotechnology

Durin Life Sciences, Inc.

Stratford, NJ · CIK 0001797306

Offering snapshot reported Jul 21, 2025 · SEC filing

Reported sold: $6.2M
Investors reported: 2
Minimum accepted: $0
First sale: Oct 17, 2023

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$3,500,000 → $6,200,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 21, 2025	Amendment	$6,200,000	$2,700,000vs Oct 27, 2023	2	SEC filing
Mar 18, 2025	Amendment	$5,499,900	$945,900vs Jan 9, 2023	3	SEC filing
Oct 27, 2023	Initial	$3,500,000	No comparison	2	SEC filing
Jan 9, 2023	Amendment	$4,554,000	$1,053,900vs Mar 23, 2021	2	SEC filing
Mar 23, 2021	Initial	$3,500,100	No comparison	2	SEC filing
Dec 19, 2019	Initial	$3,500,100	No comparison	2	SEC filing

Offering details

Securities: Debt
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-495830

Source: Form D, filed Jul 21, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Benjamin A. Belinka, Jr.	Executive
Maribeth Bluyus	Executive
Rene Chaze	Director
Robert Nagele	Director
Mert Sahin	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

2 Medical Center Dr #213 A
Stratford, NJ, 08084